020 7650 1200

Textured breast implant claims

Allergan breast implants have been removed from the market after being linked to a rare form of breast cancer

In December 2018, Allergan textured breast implants were removed from the market in Europe due to them being linked to a rare form of cancer called Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL).

Reported symptoms tend to describe a late onset of painful swollen breasts with a fluid collection usually between three and 14 years after implantation. Although investigations into the pathology of BIA-ALCL continue, positive outcomes have been reported and in most cases patients have achieved complete remission.

Register your interest

Leigh Day is currently investigating claims on behalf of women who have had a diagnosis of BIA-ALCL or are being investigated for BIA-ALCL. If you would like to speak to a member of our team regarding a potential BIA-ALCL claim, please email us.

If you have not had a diagnosis of BIA-ALCL but are concerned about developing this condition, and would like to be added to our mailing list so that we can keep you up to date on what we are doing at Leigh Day in regards to BIA-ALCL, register your interest and we can inform you if we are able to pursue legal action for you in the future.

Julie Harris had the Allergan textured breast implants in 2011. In 2018, she was diagnosed with Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Watch Julie's story

Read our blogs

Blog Post
Breast Implants Medical
Product safety consumer law Breast implants BIA-ALCL

University of Iowa Hospital leading the way in BIA-ALCL monitoring

Zahra Nanji, who represents 20 women who have the breast implant related cancer BIA-ALCL, discusses recent developments in the US

News Article
Oil damage Niger Delta
International human rights International Environmental Damage

Lawyers for women with BIA-ALCL welcome Allergan worldwide voluntary recall

Lawyers acting on behalf of 13 women who have the breast implant related cancer BIA-ALCL have welcomed the announcement from the U.S. Food and Drug Administration (FDA) that it had requested that Allergan recall specific models of its textured breast implants from the U.S. market.

Blog Post
Breast Implants
Product safety consumer law BIA-ALCL Breast implants

Early diagnosis is key in the rare cancer linked to textured breast implants

Zahra Nanji is currently investigating a legal claim for women who have Allergan textured breast implants linked to a rare form of cancer known as BIA-ALCL

Blog Post
Breast Implants Medical
BIA-ALCL Breast implants

Health Canada suspends licences for Allergan's Biocell breast implants

Zahra Nanji discusses the recent announcement by Health Canada to suspend licences for Allergan's Biocell breast implants, due to concerns about links to a rare form of cancer

What is BIA-ALCL?

Information for healthcare professionals

What is BIA-ALCL?

Information for patients